Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial
Hand-out
Press Releases
Infinitopes  
November 8, 2024

Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/IIa clinical trial

Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line patients with surgically resectable cancersInfinitopes'

avatar profile Olean Times Herald

Olean Times Herald


Local & Social